Abstract:BackgroundMetabolic reprogramming has emerged as a core hallmark of cancer, and cancer metabolism has long been equated with aerobic glycolysis. Moreover, hypoxia and the hypovascular tumor microenvironment (TME) are major hallmarks of pancreatic ductal adenocarcinoma (PDAC), in which glycolysis is imperative for tumor cell survival and proliferation. Here, we explored the impact of interleukin 1 receptor-associated kinase 2 (IRAK2) on the biological behavior of PDAC and investigated the underlying mechanism.MethodsThe expression pattern and clinical relevance of IRAK2 was determined in GEO, TCGA and Ren Ji datasets. Loss-of-function and gain-of-function studies were employed to investigate the cellular functions of IRAK2 in vitro and in vivo. Gene set enrichment analysis, Seahorse metabolic analysis, immunohistochemistry and Western blot were applied to reveal the underlying molecular mechanisms.ResultsWe found that IRAK2 is highly expressed in PDAC patient samples and is related to a poor prognosis. IRAK2 knockdown led to a significant impairment of PDAC cell proliferation via an aberrant Warburg effect. Opposite results were obtained after exogenous IRAK2 overexpression. Mechanistically, we found that IRAK2 is critical for sustaining the activation of transcription factors such as those of the nuclear factor-κB (NF-κB) family, which have increasingly been recognized as crucial players in many steps of cancer initiation and progression. Treatment with maslinic acid (MA), a NF-κB inhibitor, markedly attenuated the aberrant oncological behavior of PDAC cells caused by IRAK2 overexpression.ConclusionsOur data reveal a role of IRAK2 in PDAC metabolic reprogramming. In addition, we obtained novel insights into how immune-related pathways affect PDAC progression and suggest that targeting IRAK2 may serve as a novel therapeutic approach for PDAC.

Homeodomain-interacting Protein Kinase 2 Suppresses Proliferation and Aerobic Glycolysis Via ERK/cMyc Axis in Pancreatic Cancer

Identification of Spindle and Kinetochore-Associated Family Genes As Therapeutic Targets and Prognostic Biomarkers in Pancreas Ductal Adenocarcinoma Microenvironment

Inactivation of HIPK2 attenuates KRASG12D activity and prevents pancreatic tumorigenesis

HIPK2 Suppresses Tumor Growth and Progression of Hepatocellular Carcinoma Through Promoting the Degradation of HIF-1α

A Potential Biomarker for Tumor Progression and Response to Therapies

Data from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Hipk2 Represses Beta-Catenin-Mediated Transcription, Epidermal Stem Cell Expansion, and Skin Tumorigenesis

SUPPLEMENTARY DATA FIGURES from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Hexokinase 2 nonmetabolic function‐mediated phosphorylation of IκBα enhances pancreatic ductal adenocarcinoma progression

YY1 Targets Tubulin Polymerisation-Promoting Protein to Inhibit Migration, Invasion and Angiogenesis in Pancreatic Cancer Via P38/mapk and PI3K/AKT Pathways

Correlation Between Homeodomain-Interacting Protein Kinase 2 and Apoptosis in Cervical Cancer.

Reduction of Hip2 Suppresses Gastric Cancer Cell Proliferation, Migration, Invasion and Tumorigenesis

PKM2 regulates neural invasion of and predicts poor prognosis for human hilar cholangiocarcinoma

Kindlin-2 enhances c-Myc translation through association with DDX3X to promote pancreatic ductal adenocarcinoma progression

Hexokinase 2 Regulates G1/S Checkpoint Through CDK2 in Cancer-Associated Fibroblasts.

IRAK2-NF-κB signaling promotes glycolysis-dependent tumor growth in pancreatic cancer

Pyruvate kinase M2 promotes pancreatic ductal adenocarcinoma invasion and metastasis through phosphorylation and stabilization of PAK2 protein

KIF2C Facilitates Tumor Growth and Metastasis in Pancreatic Ductal Adenocarcinoma

Epigenetic Silencing of LncRNA LINC00261 Promotes C-Myc-mediated Aerobic Glycolysis by Regulating Mir-222-3p/hipk2/erk Axis and Sequestering IGF2BP1

The c-Myc–LDHA axis positively regulates aerobic glycolysis and promotes tumor progression in pancreatic cancer

C-Jun N-terminal Kinase 2 Suppresses Pancreatic Cancer Growth and Invasion and is Opposed by C-Jun N-terminal Kinase 1.